文献速递神经肿瘤

miR-21作为胶质瘤诊断与预后生物标志物:巴基斯坦队列的组织与血清表达分析

miR-21 as a diagnostic and prognostic biomarker in glioma: tissue and serum expression analysis in a Pakistani cohort.
PubMed 文献 · J Neurooncol · 2025-10-22

该研究在巴基斯坦队列中采用RT-qPCR检测90例胶质瘤组织、42对配对术前术后血清及对照样本的miR-21表达,发现其随肿瘤级别升高而升高,与IDH野生型、高Ki-67及不良生存相关,术后血清miR-21显著下降,提示其可作为组织预后标志物和血清监测工具。

要点

  • miR-21在高级别及IDH野生型胶质瘤中表达显著升高。
  • 高表达组死亡风险为低表达组的3.4倍(95%CI 1.6-7.1)。
  • 术后血清miR-21较术前显著下降,支持其用于肿瘤监测。

核心结论

  • miR-21在胶质瘤组织和血清中显著上调,尤其在高 grade 和IDH野生型肿瘤中。
  • miR-21与不良临床结局和侵袭性分子特征强相关,其预后价值在单独及联合已建立标志物时均稳健。
  • 术后血清miR-21动态变化提示其可用于疾病监测,组织结果与全球数据一致,血清结果需进一步验证。

研究设计与样本

  • 研究收集90例胶质瘤组织样本、42对配对术前术后血清、10例正常邻近脑组织及8例健康个体血清,采用RT-qPCR检测miR-21表达。
  • 使用Shapiro-Wilk检验评估数据分布,并应用ANOVA、Fisher精确检验、Wilcoxon检验和成对Student t检验分析基因表达差异。

主要发现

  • miR-21在胶质瘤组织中的表达随肿瘤级别升高而逐渐增加,4级与对照组织间差异显著,1级与4级、2级与4级间也有显著差异。
  • IDH野生型和高Ki-67表达的胶质瘤中miR-21水平显著高于IDH突变型和低Ki-67组。
  • 低miR-21表达患者的总生存期显著长于高表达患者,高表达组死亡风险增加3.4倍(95%CI 1.6-7.1),AUC为0.742(均p<0.05)。
  • 50岁以上患者中miR-21表达显著升高。
  • 血清miR-21在健康对照组和术后样本中显著低于术前样本(2、3、4级胶质瘤患者),提示其作为非侵入性诊断和监测标志物的潜力。

临床怎么用

  • miR-21可作为组织为基础的预后标志物,用于胶质瘤风险分层。
  • 血清miR-21动态监测可能辅助术后肿瘤监测,尤其在低中收入国家。
  • 联合IDH、Ki-67等标志物可增强预后评估。

局限性

  • 队列样本量有限且级别分布不均衡,限制了预后意义的确定性。
  • 血清结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gliomas are heterogeneous primary brain tumors with a poor prognosis, particularly in higher grades. MicroRNA-21 (miR-21) has emerged as a potential oncogenic biomarker in various cancers, including gliomas; however, its clinical utility in low- and middle-income countries (LMICs) remains underexplored. This study investigates the prognostic and diagnostic potential of miR-21 in glioma tissues and serum, examining its association with clinical and molecular features, tumor volume, and patient survival. METHODOLOGY: We collected 90 tumor tissue samples, 42 paired pre-and post-operative serum samples from glioma patients, and 10 normal adjacent brain tissue (NAT) samples, along with serum samples from 8 healthy individuals, to assess miR-21 expression using RT-qPCR. The Shapiro-Wilk test was performed to evaluate the data distribution. To analyze differences in gene expression, we applied ANOVA, Fisher's exact test, the Wilcoxon test, and pairwise Student's t-tests. miR-21 expression levels were further examined for correlation with Kaplan-Meier survival curves and the status of molecular markers, including IDH, Ki-67, ATRX, and p53. The hazard ratio for miR-21 as a prognostic indicator was quantified using Cox regression analysis. RESULTS: MicroRNA-21 expression in glioma tissue progressively increased with tumor grade when compared to controls and across different glioma grades. A significant elevation in miR-21 expression was observed between grade 4 glioma tissues and control tissues, with additional significant differences between grade 1 and grade 4, as well as between grade 2 and grade 4. While tissue expression of miR-21 showed a positive trend with tumor volume, this correlation did not reach statistical significance. Moreover, gliomas with IDH-wildtype status and high Ki-67 expression demonstrated significantly higher miR-21 levels compared to IDH-mutant and low Ki-67 groups, respectively. Patients with low miR-21 expression had significantly longer overall survival (OS) compared to those with high miR-21 expression levels. Quantitative hazard analysis revealed that patients in the high-expression group had a 3.4-fold increased risk of mortality (95% CI: 1.6-7.1), with an AUC of 0.742 (all p < 0.05). Notably, significantly elevated miR-21 expression was found in patients over the age of 50. In serum samples, miR-21 expression was significantly lower in the healthy control group and in post-operative samples compared to pre-operative samples across grades 2, 3, and 4 glioma patients. This suggests its potential utility as a non-invasive diagnostic and monitoring biomarker. The decline in serum miR-21 levels following tumor resection supports its association with tumor presence and progression. However, the prognostic significance was limited by cohort size and grade imbalance. CONCLUSION: miR-21 is significantly upregulated in both glioma tissue and serum, particularly in high-grade and IDH-wildtype tumors. It is strongly associated with poor clinical outcomes and aggressive molecular features. Its prognostic value is robust both alone and in combination with established markers. Furthermore, dynamic changes in serum miR-21 levels post-surgery highlight its potential utility in disease monitoring. These findings support the incorporation of miR-21 into glioma diagnostic and prognostic frameworks, enhancing clinical decision-making and personalized treatment approaches. miR-21 serves as a strong tissue-based prognostic marker in gliomas and a promising serum biomarker for tumor monitoring. While tissue findings align with global data, further studies are required to validate the serum results. This work underscores the clinical relevance of miR-21 in low- and middle-income countries (LMICs), where non-invasive tools are urgently needed.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Laghari AA, Sufiyan S, Amin W, et al. miR-21 as a diagnostic and prognostic biomarker in glioma: tissue and serum expression analysis in a Pakistani cohort. J Neurooncol. 2025. PMID: 41123727. doi:10.1007/s11060-025-05287-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。